Achaogen Inc (NASDAQ:AKAO) has been assigned an average rating of “Hold” from the twelve ratings firms that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell recommendation and ten have issued a hold recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $2.71.
Several equities analysts have weighed in on the company. Zacks Investment Research cut Achaogen from a “buy” rating to a “hold” rating in a research note on Thursday, April 11th. Needham & Company LLC restated a “hold” rating on shares of Achaogen in a research note on Friday, March 29th. Finally, HC Wainwright restated a “hold” rating and set a $2.00 price objective on shares of Achaogen in a research note on Thursday, February 21st.
Shares of NASDAQ:AKAO opened at $0.11 on Friday. The company has a current ratio of 0.78, a quick ratio of 0.77 and a debt-to-equity ratio of 1.00. Achaogen has a 1-year low of $0.10 and a 1-year high of $15.00. The firm has a market cap of $7.03 million, a price-to-earnings ratio of -0.03 and a beta of 0.78.
Achaogen Company Profile
Achaogen, Inc, a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.
Featured Article: Investing strategies using the yield curve
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.